Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Debt to Equity (2021)

ARS Pharmaceuticals (SPRY) has disclosed Debt to Equity for 1 consecutive years, with -$0.16 as the latest value for Q4 2021.

  • Quarterly Debt to Equity changed N/A to -$0.16 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$0.16 through Dec 2021, changed N/A year-over-year, with the annual reading at -$0.16 for FY2021, N/A changed from the prior year.
  • Debt to Equity hit -$0.16 in Q4 2021 for ARS Pharmaceuticals, down from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.0 in Q1 2021 to a low of -$0.16 in Q4 2021.